APP13007の新興薬剤に関する洞察と市場予測：2032年

APP13007は、術後の眼炎症治療薬として開発中のコルチコステロイド・クロベタゾールのナノ粒子製剤です。Activus社は当初、特許取得済みの独自技術であるActivus Pure Nanoparticle Technology（APNT）を副腎皮質ステロイド薬であるプロピオン酸クロベタゾールに応用し、眼の術後炎症治療用の新規ナノ粒子製剤を創製することでAPP13007を開発しました。奏効率は、APP13007がフェーズIIIの重要な評価項目である炎症と疼痛の軽減において競合薬を上回ることを強く示唆しています。

APP13007は2020年に第II相試験を完了し、2021年3月に米国で第III相試験を開始しました。

2022年8月、Formosa Pharmaceuticals, Inc.とAimMax Therapeutics, Inc.は、APP13007の2つの重要な第III相臨床試験のうち、2番目の試験であるCPN-302のトップライン結果が良好であったと報告しました。

当レポートでは、主要8ヶ国におけるAPP13007市場について調査し、市場の概要とともに、2023年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 急性眼痛に対するAPP13007の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 APP13007市場評価

• 急性眼痛に対するAPP13007の市場展望
• 主要8ヶ国市場分析
  • 主要8ヶ国市場における急性眼痛に対するAPP13007の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国
  • カナダ
  • 韓国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: APP13007, Clinical Trial Description, 2023
• Table 2: APP13007, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: APP13007 Market Size in the 8MM, in USD million (2019-2032)
• Table 6: APP13007 Market Size in the US, in USD million (2019-2032)
• Table 7: APP13007 Market Size in Germany, in USD million (2019-2032)
• Table 8: APP13007 Market Size in France, in USD million (2019-2032)
• Table 9: APP13007 Market Size in Italy, in USD million (2019-2032)
• Table 10: APP13007 Market Size in Spain, in USD million (2019-2032)
• Table 11: APP13007 Market Size in the UK, in USD million (2019-2032)
• Table 12: APP13007 Market Size in Canada, in USD million (2019-2032)
• Table 13: APP13007 Market Size in South Korea, in USD million (2019-2032)

List of Figures

• Figure 1: APP13007 Market Size in the 8MM, USD million (2019-2032)
• Figure 2: APP13007 Market Size in the United States, USD million (2019-2032)
• Figure 3: APP13007 Market Size in Germany, USD million (2019-2032)
• Figure 4: APP13007 Market Size in France, USD million (2019-2032)
• Figure 5: APP13007 Market Size in Italy, USD million (2019-2032)
• Figure 6: APP13007 Market Size in Spain, USD million (2019-2032)
• Figure 7: APP13007 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: APP13007 Market Size in Canada, USD million (2019-2032)
• Figure 9: APP13007 Market Size in South Korea, USD million (2019-2032)

“"APP13007 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about APP13007 for acute ocular pain (AOP) in the eight major markets. A detailed picture of the APP13007 for acute ocular pain in the 8MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Canada and South Korea for the study period 2019 -2032 is provided in this report along with a detailed description of the APP13007 for acute ocular pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the APP13007 market forecast analysis for acute ocular pain in the 8MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in acute ocular pain.

Drug Summary:

APP13007 is a nanoparticle formulation of the corticosteroid clobetasol in development for treating postoperative inflammation of the eye. Activus initially developed APP13007 by applying its patented proprietary Activus Pure Nanoparticle Technology (APNT) to the corticosteroid clobetasol propionate to create a novel nanoparticle formulation for treating postoperative inflammation of the eye. Response rate strongly suggests APP13007 outperforms competitors in reducing inflammation and pain for critical Phase III endpoints.

APP13007 completed Phase II studies in 2020 and started Phase III studies in the United States in March 2021.

In Aug 2022, Formosa Pharmaceuticals, Inc. and AimMax Therapeutics, Inc. (United States) reported successful top-line results from CPN-302, the second of the two pivotal Phase III clinical studies of APP13007.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the APP13007 description, mechanism of action, dosage and administration, research and development activities in acute ocular pain.
• Elaborated details on APP13007 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the APP13007 research and development activities in acute ocular pain across the United States, Europe, Canada and South Korea.
• The report also covers the patents information with expiry timeline around APP13007.
• The report contains forecasted sales of APP13007 for acute ocular pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for acute ocular pain.
• The report also features the SWOT analysis with analyst views for APP13007 in acute ocular pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

APP13007 Analytical Perspective by DelveInsight

In-depth APP13007 Market Assessment

This report provides a detailed market assessment of APP13007 for acute ocular pain in the eight major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Canada and South Korea. This segment of the report provides forecasted sales data from 2023 to 2032.

APP13007 Clinical Assessment

The report provides the clinical trials information of APP13007 for acute ocular pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for acute ocular pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence APP13007 dominance.
• Other emerging products for acute ocular pain are expected to give tough market competition to APP13007 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of APP13007 in acute ocular pain.
• Our in-depth analysis of the forecasted sales data of APP13007 from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the APP13007 in acute ocular pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of APP13007?
• What is the clinical trial status of the study related to APP13007 in acute ocular pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the APP13007 development?
• What are the key designations that have been granted to APP13007 for acute ocular pain?
• What is the forecasted market scenario of APP13007 for acute ocular pain?
• What are the forecasted sales of APP13007 in the eight major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, Canada and South Korea?
• What are the other emerging products available and how are these giving competition to APP13007 for acute ocular pain?
• Which are the late-stage emerging therapies under development for the treatment of acute ocular pain?

Table of Contents

1. Report Introduction

2. APP13007 Overview in Acute ocular pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. APP13007 Market Assessment

• 5.1. Market Outlook of APP13007 in Acute ocular pain
• 5.2. 8MM Analysis
  • 5.2.1. Market Size of APP13007 in the 8MM for Acute ocular pain
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of APP13007 in the United States for Acute ocular pain
  • 5.3.2. Market Size of APP13007 in Germany for Acute ocular pain
  • 5.3.3. Market Size of APP13007 in France for Acute ocular pain
  • 5.3.4. Market Size of APP13007 in Italy for Acute ocular pain
  • 5.3.5. Market Size of APP13007 in Spain for Acute ocular pain
  • 5.3.6. Market Size of APP13007 in the United Kingdom for Acute ocular pain
  • 5.3.7. Market Size of APP13007 in Canada for Acute ocular pain
  • 5.3.8. Market Size of APP13007 in South Korea for Acute ocular pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options